Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients

Completed · Phase 4

Conditions studied: Hypertension

In brief

The purpose of this study is to determine if Nebivolol a) attenuates the angiotensin II (Ang II)-induced increase in oxidative stress, thereby attenuating Ang II-induced vasoconstriction; and b) attenuates sympathetic mediated vasoconstriction during exercise, thereby reducing functional skeletal muscle ischemia in hypertensive patients.

Key facts

Study ID

NCT01502787

Run by

University of Texas Southwestern Medical Center

People needed

46

Starts

2009-04-01

Expected to finish

2013-06-01

Last updated by the study team

2020-07-07

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Stage I hypertension (140-159/90-99 mmHg)
• Men and women age 18-65

You may not qualify if…

• Congestive heart failure or coronary artery disease
• Blood pressure averaging >159/99 mmHg or resting heart rate < 55 bpm
• Serum creatinine > 1.4 mg/dL
• Asthma or chronic obstructive pulmonary diseases
• Left ventricular hypertrophy by echocardiography or ECG
• Pregnancy
• Hypersensitivity to beta blockers, microbubble contrast agents, or angiotensin
• Any history of substance abuse (other than tobacco)
• Concomitant drug treatment which raises endogenous nitric oxide levels such as nitrates or phosphodiesterase V inhibitors (Viagra, Levitra, or Cialis)
• History of symptomatic bradycardia or heart block

Where it is running

• UT Southwestern Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.